A medical device manufacturer ThermoGenesis (NASDAQ: THMO) pops at least 39% in premarket while healthcare stocks tend to surge further as COVID-19 vaccine developers push many biotech shares upward.
April was a lucky month for THMO with a surging trend that increased the enormous demand for its shares. It seems that kind of month is coming in September despite having a negative EPS. Cash-burning ThermoGenesis might start earning soon as the revenue reaches new high levels.
Its actual value is far less than the market cap which was a result of increasing demand for its cheap shares that cost around $5 now. For short term investors, it might be the right time to join THMO with little spending, perhaps $500.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.